Table 2. Effect estimates from multivariable-adjusted Cox regression models for the effect of cytogenetic high-risk abnormalities on overall survival in the entire cohort and patient subgroups.
Parameter | Reference | HR (95% CI) | P-value |
---|---|---|---|
Effect of multiple HRA in the entire cohort (using ISS, n=1181) | |||
1 HRA | 0 HRA | 1.65 (1.32–2.05) | <0.001 |
2 HRA | 0 HRA | 3.15 (2.00–4.96) | <0.001 |
Effect of multiple HRA in the entire cohort (using R-ISS, n=1087) | |||
1 HRA | 0 HRA | 1.47 (1.16–1.86) | 0.001 |
2 HRA | 0 HRA | 2.69 (1.69–4.30) | <0.001 |
Effect of specific HRA in the entire cohort (using ISS, n=1181) | |||
del(17p) | Absence of del(17p) | 1.64 (1.29–2.08) | <0.001 |
HRT | Absence of HRT | 1.78 (1.39–2.30) | <0.001 |
Effect of specific HRA in the entire cohort (using R-ISS, n=1087) | |||
del(17p) | Absence of del(17p) | 1.49 (1.16–1.91) | 0.002 |
HRT | Absence of HRT | 1.62 (1.24–2.11) | <0.001 |
Effect of specific additional HRA (using ISS, n=164 and n=154) | |||
del(17p)+HRT | Isolated del(17p) | 2.08 (1.19–3.63) | 0.010 |
del(17p)+HRT | Isolated HRT | 1.86 (1.07–3.22) | 0.027 |
Abbreviations: CI, confidence interval; HR, hazard ratio; HRA, cytogenetic high-risk abnormality. HRT: High-risk translocation.
All models were adjusted for age, sex, International Staging System (ISS) or revised ISS (R-ISS) stage, and first-line therapy (immunomodulator, proteasome inhibitor, upfront autologous hematopoietic stem cell transplantation).